INDSWIFT LABORATORIES
|
INDSWIFT LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 36.44 | 71.24 | 8.06 | -0.36 | -0.53 |
| CEPS(Rs) | 40.00 | 80.35 | 17.80 | 21.81 | 14.24 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 159.86 | 157.64 | 84.25 | 68.33 | 66.35 |
| Tax Rate(%) | 2.82 | 27.56 | 44.72 | 117.15 | 117.48 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -3.36 | 19.71 | 18.90 | 18.66 | 20.35 |
| EBIT Margin(%) | 45.24 | 49.07 | 14.74 | 10.31 | 13.16 |
| Pre Tax Margin(%) | 44.74 | 45.11 | 7.14 | 1.20 | 2.01 |
| PAT Margin (%) | 43.48 | 32.68 | 3.94 | -0.21 | -0.35 |
| Cash Profit Margin (%) | 47.72 | 36.81 | 8.68 | 12.30 | 9.37 |
| Performance Ratios | |||||
| ROA(%) | 19.83 | 28.79 | 2.70 | -0.12 | -0.18 |
| ROE(%) | 24.68 | 58.97 | 10.61 | -0.54 | -0.78 |
| ROCE(%) | 24.24 | 55.13 | 13.25 | 7.88 | 8.31 |
| Asset Turnover(x) | 0.46 | 0.88 | 0.68 | 0.60 | 0.51 |
| Sales/Fixed Asset(x) | 2.00 | 1.93 | 0.92 | 0.80 | 0.67 |
| Working Capital/Sales(x) | 0.89 | 2.93 | 1.53 | 1.42 | 1.43 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.50 | 0.52 | 1.09 | 1.25 | 1.48 |
| Receivable days | 105.66 | 95.44 | 144.51 | 154.46 | 168.41 |
| Inventory Days | 39.47 | 63.55 | 130.51 | 140.01 | 145.99 |
| Payable days | 129.43 | 82.21 | 105.77 | 106.89 | 110.78 |
| Valuation Parameters | |||||
| PER(x) | 2.30 | 1.38 | 6.86 | - | - |
| PCE(x) | 2.10 | 1.22 | 3.10 | 3.04 | 5.06 |
| Price/Book(x) | 0.53 | 0.62 | 0.66 | 0.97 | 1.09 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.32 | 0.13 | 0.96 | 1.26 | 1.59 |
| EV/Core EBITDA(x) | 2.94 | 0.54 | 4.42 | 5.49 | 6.90 |
| EV/EBIT(x) | 0.70 | 0.26 | 6.49 | 12.15 | 12.00 |
| EV/CE(x) | 0.15 | 0.17 | 0.86 | 0.75 | 0.81 |
| M Cap / Sales | 1.03 | 0.45 | 0.27 | 0.38 | 0.48 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -56.15 | 6.10 | 16.23 | 16.54 | 14.33 |
| Core EBITDA Growth(%) | -79.31 | 14.04 | 9.86 | 16.35 | 16.15 |
| EBIT Growth(%) | -58.80 | 254.17 | 65.33 | -8.58 | 36.08 |
| PAT Growth(%) | -40.56 | 781.13 | 2,325.72 | 31.72 | 85.15 |
| EPS Growth(%) | -48.86 | 784.43 | 2,314.84 | 31.72 | 85.15 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.03 | 0.01 | 1.71 | 2.33 | 2.56 |
| Current Ratio(x) | 3.92 | 2.99 | 3.13 | 3.21 | 2.99 |
| Quick Ratio(x) | 3.41 | 2.94 | 1.95 | 1.93 | 1.80 |
| Interest Cover(x) | 89.31 | 12.38 | 1.94 | 1.13 | 1.18 |
| Total Debt/Mcap(x) | 0.06 | 0.02 | 2.61 | 2.40 | 2.36 |
Compare Financial Ratios of peers of INDSWIFT LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDSWIFT LABORATORIES | ₹742.3 Cr | -5.1% | -9.3% | -4.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹426,170.0 Cr | -0.2% | 6.1% | 0.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹167,038.0 Cr | -1.4% | -4.9% | 3.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹127,357.0 Cr | 0.8% | 5% | 12.9% | Stock Analytics | |
| CIPLA | ₹120,414.0 Cr | -1.3% | -0.5% | 1.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,015.0 Cr | -0.7% | 5.1% | 4.9% | Stock Analytics | |
INDSWIFT LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDSWIFT LABORATORIES | -5.1% |
-9.3% |
-4.5% |
| SENSEX | -0.6% |
1.7% |
4.6% |
You may also like the below Video Courses
